JP2020518287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518287A5 JP2020518287A5 JP2020511867A JP2020511867A JP2020518287A5 JP 2020518287 A5 JP2020518287 A5 JP 2020518287A5 JP 2020511867 A JP2020511867 A JP 2020511867A JP 2020511867 A JP2020511867 A JP 2020511867A JP 2020518287 A5 JP2020518287 A5 JP 2020518287A5
- Authority
- JP
- Japan
- Prior art keywords
- modified fgf
- polypeptide
- recombinant modified
- seq
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 19
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 2
- 201000007717 corneal ulcer Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000028006 Corneal injury Diseases 0.000 claims 1
- 208000020564 Eye injury Diseases 0.000 claims 1
- 208000028990 Skin injury Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 210000002159 anterior chamber Anatomy 0.000 claims 1
- 238000005422 blasting Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000871 endothelium corneal Anatomy 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 102220231685 rs1064797227 Human genes 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024075396A JP2024112824A (ja) | 2017-05-05 | 2024-05-07 | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502540P | 2017-05-05 | 2017-05-05 | |
| US201762502529P | 2017-05-05 | 2017-05-05 | |
| US62/502,529 | 2017-05-05 | ||
| US62/502,540 | 2017-05-05 | ||
| US201762584624P | 2017-11-10 | 2017-11-10 | |
| US62/584,624 | 2017-11-10 | ||
| PCT/US2018/031189 WO2018204847A2 (en) | 2017-05-05 | 2018-05-04 | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024075396A Division JP2024112824A (ja) | 2017-05-05 | 2024-05-07 | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020518287A JP2020518287A (ja) | 2020-06-25 |
| JP2020518287A5 true JP2020518287A5 (enExample) | 2021-06-17 |
Family
ID=64016756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511867A Pending JP2020518287A (ja) | 2017-05-05 | 2018-05-04 | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
| JP2024075396A Pending JP2024112824A (ja) | 2017-05-05 | 2024-05-07 | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024075396A Pending JP2024112824A (ja) | 2017-05-05 | 2024-05-07 | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11479591B2 (enExample) |
| EP (2) | EP4621067A3 (enExample) |
| JP (2) | JP2020518287A (enExample) |
| KR (1) | KR20200078425A (enExample) |
| CN (1) | CN111148755A (enExample) |
| AU (1) | AU2018261021B2 (enExample) |
| BR (1) | BR112019023260A2 (enExample) |
| CA (1) | CA3062473A1 (enExample) |
| DK (1) | DK3619324T3 (enExample) |
| ES (1) | ES3041527T3 (enExample) |
| MX (1) | MX2019013210A (enExample) |
| WO (1) | WO2018204847A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200078425A (ko) | 2017-05-05 | 2020-07-01 | 트레포일 테라퓨틱스, 인크. | 재조합 변형된 섬유아세포 성장 인자 및 이의 치료적 용도 |
| CN116710568A (zh) | 2020-06-26 | 2023-09-05 | 特里福伊尔治疗公司 | 重组修饰成纤维细胞生长因子及其治疗用途 |
| JP2023531480A (ja) | 2020-06-26 | 2023-07-24 | エルティー・マテリアルズ・カンパニー・リミテッド | ヘテロ環化合物およびそれを用いた有機発光素子 |
| EP4574211A3 (en) * | 2021-05-14 | 2025-09-10 | Claris Biotherapeutics, Inc. | Compositions of growth factor for the treatment of eye disease |
| CN113289005B (zh) * | 2021-07-06 | 2022-05-31 | 温州医科大学 | rhFGF-21在制备治疗干眼症药物中的应用 |
| WO2023019218A1 (en) * | 2021-08-12 | 2023-02-16 | Trefoil Therapeutics, Inc. | Modified fibroblast growth factors for treating fibrotic diseases |
| US12357843B2 (en) | 2022-03-25 | 2025-07-15 | Cutera, Inc. | Methods of skin treatment with laser light |
| CN115177717B (zh) * | 2022-08-31 | 2026-02-06 | 贵州医科大学附属医院 | 一种治疗眼表及角膜上皮疾病的药物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552528A (en) * | 1986-03-03 | 1996-09-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bovine b-endothelial cell growth factor |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| GB2223496B (en) | 1988-08-08 | 1992-05-27 | British Bio Technology | Synthetic gene encoding mature human acid fibroblast growth factor |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
| US20010006939A1 (en) * | 1997-10-03 | 2001-07-05 | Ralph W. Niven | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| US6642026B2 (en) * | 2000-08-15 | 2003-11-04 | Phage Biotechnology Corporation | Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
| AU1628101A (en) | 1999-11-22 | 2001-06-04 | Millennium Pharmaceuticals, Inc. | Jaffa, a novel fibroblast growth factor family member and uses therefor |
| US20050227929A1 (en) | 2003-11-13 | 2005-10-13 | Masferrer Jaime L | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent |
| US7790682B1 (en) | 2003-12-02 | 2010-09-07 | The Florida State University Research Foundation, Inc. | Engineered human acidic fibroblast growth factors and associated methods |
| AU2004303783A1 (en) * | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| ATE513823T1 (de) * | 2004-08-17 | 2011-07-15 | Simpson Biotech Co Ltd | Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung |
| US7776825B1 (en) | 2006-11-09 | 2010-08-17 | Florida State University Research Foundation, Incorporated | Mutant polypeptides of fibroblast growth factor 1 |
| US7659379B1 (en) | 2007-05-24 | 2010-02-09 | Florida State University Research Foundation, Inc. | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency |
| PL2245056T4 (pl) * | 2008-01-22 | 2016-01-29 | Araim Pharmaceuticals Inc | Peptydy i analogi peptydowe chroniące tkanki do zapobiegania i leczenia chorób i schorzeń związanych z uszkodzeniem tkanek |
| US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
| US20110224404A1 (en) | 2010-03-11 | 2011-09-15 | Florida State University Research Foundation | Method for development of a peptide building block useful for de novo protein design |
| UY34346A (es) * | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de fusión para tratar trastornos metabólicos |
| US20150253308A1 (en) * | 2013-05-03 | 2015-09-10 | Orasis | Compositions and methods of treating glaucoma |
| HRP20200257T1 (hr) | 2013-09-25 | 2020-09-04 | Trefoil Therapeutics, Llc | Izmjenjeni faktori rasta fibroblasta-1 za liječenje okularnih poremećaja |
| TWI634898B (zh) * | 2013-10-07 | 2018-09-11 | 雅祥生技醫藥股份有限公司 | 經修飾之人類酸性纖維母細胞生長因子及其組合物 |
| US20150104494A1 (en) * | 2013-10-11 | 2015-04-16 | Ohio State Innovation Foundation | Methods for repair of ear canal tissue defects |
| CA2928135A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (fgf) 1 and methods of use |
| WO2015198175A1 (en) * | 2014-06-27 | 2015-12-30 | Florida State University Research Foundation, Inc. | Design of fgf-1 mutants to effectively eliminate reactive cysteine residues |
| CA2983153A1 (en) | 2015-04-20 | 2016-10-27 | Salk Institute For Biological Studies | Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose |
| AU2016252426A1 (en) * | 2015-04-20 | 2017-11-23 | Salk Institute For Biological Studies | Fibroblast growth factor (FGF) 1 mutants and methods of use to reduce blood glucose |
| JP6559239B2 (ja) * | 2015-08-13 | 2019-08-14 | 富士フイルム株式会社 | 多能性幹細胞の培養方法、培養容器の製造方法、培養容器、及び細胞培養用の足場材料 |
| KR20200078425A (ko) | 2017-05-05 | 2020-07-01 | 트레포일 테라퓨틱스, 인크. | 재조합 변형된 섬유아세포 성장 인자 및 이의 치료적 용도 |
-
2018
- 2018-05-04 KR KR1020197035895A patent/KR20200078425A/ko not_active Ceased
- 2018-05-04 BR BR112019023260-5A patent/BR112019023260A2/pt not_active IP Right Cessation
- 2018-05-04 AU AU2018261021A patent/AU2018261021B2/en active Active
- 2018-05-04 WO PCT/US2018/031189 patent/WO2018204847A2/en not_active Ceased
- 2018-05-04 ES ES18794391T patent/ES3041527T3/es active Active
- 2018-05-04 MX MX2019013210A patent/MX2019013210A/es unknown
- 2018-05-04 DK DK18794391.5T patent/DK3619324T3/da active
- 2018-05-04 EP EP25181506.4A patent/EP4621067A3/en active Pending
- 2018-05-04 JP JP2020511867A patent/JP2020518287A/ja active Pending
- 2018-05-04 US US16/611,182 patent/US11479591B2/en active Active
- 2018-05-04 EP EP18794391.5A patent/EP3619324B1/en active Active
- 2018-05-04 CA CA3062473A patent/CA3062473A1/en active Pending
- 2018-05-04 CN CN201880044863.5A patent/CN111148755A/zh active Pending
-
2022
- 2022-09-07 US US17/939,238 patent/US20230130851A1/en active Pending
-
2024
- 2024-05-07 JP JP2024075396A patent/JP2024112824A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518287A5 (enExample) | ||
| JP4310588B2 (ja) | 新規ペプチドおよびその医薬用途 | |
| JP2019533722A5 (enExample) | ||
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| CA2961029A1 (en) | Peptidomimetic macrocycles and formulations thereof | |
| JP2024112824A (ja) | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 | |
| JP2016519132A (ja) | アンジオテンシンペプチドによる眼外傷の修復促進 | |
| KR20220079860A (ko) | 신규 펩티드 | |
| JP2020183391A (ja) | チモシンベータ４を含む眼科用製剤の製造方法 | |
| JP4249025B2 (ja) | ドライアイおよびドライアイを伴う疾病の治療剤 | |
| JP2009500045A5 (enExample) | ||
| US20170209498A1 (en) | Methods for treating ocular contusion and blunt injury and traumatic injury of the optic nerve | |
| KR101838759B1 (ko) | 점안제 | |
| JP2010524910A5 (enExample) | ||
| RU2018140501A (ru) | Пэгилированные биологически активные пептиды и их применение | |
| JP2019522046A5 (enExample) | ||
| JP2019516675A5 (enExample) | ||
| JP2019519466A5 (enExample) | ||
| JP2014512369A5 (enExample) | ||
| JPWO2005102375A1 (ja) | Ｐａｃａｐおよびその誘導体を含有する角膜神経突起形成促進剤 | |
| RU2013103487A (ru) | Вакцинотерапия неоваскуляризации сосудистой оболочки глаза | |
| US10501511B2 (en) | Low molecular polypeptide for preventing and treating inflammation and use thereof | |
| JP7832745B2 (ja) | 網膜色素上皮細胞の保護剤 | |
| JP2023517459A (ja) | 眼科用医薬組成物及びその使用 | |
| JP2016519110A5 (enExample) |